公开(公告)号：US10682334B2

公开(公告)日：2020-06-16

申请号：US16166357

申请日：2018-10-22

Applicant: DSM IP ASSETS B.V.

Inventor： Szabolcs Peter ,  Joseph Schwager ,  Weerasinghe M. Indrasena ,  Jaroslav A. Kralovec ,  Bernd Mussler

IPC: A61K31/355 ,  A61P1/16 ,  A61K31/22

Abstract: The present invention relates to the use of mixtures of vitamin E and polyunsaturated fatty acids (PUFAs) as agents for the prevention, control and/or treatment of conditions associated with excessive fat accumulation in the liver which is not caused by alcohol abuse. This includes prevention, control and/or treatment of non-alcoholic steatosis in the liver—known as non-alcoholic fatty liver disease (NAFLD)—and/or non-alcoholic steatohepatitis (NASH) in a subject in need thereof. In particular, the present invention relates to the use of such compounds comprising vitamin E acetate and DHA EE as active ingredients in the manufacture of medicaments for the prevention, control and/or treatment of conditions related to NAFLD.

公开(公告)号：US10357501B2

公开(公告)日：2019-07-23

申请号：US15393160

申请日：2016-12-28

Applicant: DSM IP ASSETS B.V.

Inventor： Stephanie Krammer-Lukas ,  Elisabeth Stoecklin ,  Joseph Schwager ,  Swen Wolfram

IPC: A61K31/59 ,  A61K47/00 ,  A61K31/593 ,  A23L33/155 ,  A61K9/00 ,  A61K9/48

Abstract: Methods for treating/preventing conditions associated with an increased level of eotaxin in a human with 25-hydroxyvitamin D3 (calcifediol) are provided. Optionally, vitamin D3 may be used together with 25-hydroxyvitamin D3.

公开(公告)号：US11026916B2

公开(公告)日：2021-06-08

申请号：US16453934

申请日：2019-06-26

Applicant: DSM IP ASSETS B.V.

Inventor： Szabolcs Peter ,  Joseph Schwager

IPC: A61K31/355 ,  A61K31/202 ,  A23L33/12 ,  A23L33/15 ,  A61P1/16 ,  A61K31/22

Abstract: Mixtures of vitamin E and polyunsaturated fatty acids (PUFAs) are provided as agents for the prevention, control and/or treatment of conditions associated with excessive fat accumulation in the liver which is not caused by alcohol abuse, including control and/or treatment of non-alcoholic steatosis in the liver—known as non-alcoholic fatty liver disease (NAFLD)—and/or non-alcoholic steatohepatitis (NASH) in a subject in need thereof.